Evaluation of pefloxacin efficacy and tolerability in the treatment and profilaxy of severe infections at the children with mucoviscidosis and aplastic anemia

Antibiotiki i Khimioterapiya

Volumn 45, Issue 8, 2000, Pages 25-30

  Postnikov, S S ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Aplastic anemia; Bronchopulmonary process; Mucoviscidosis; Pefloxacin; Quinolone induced arthropathy

Indexed keywords

ANTIINFECTIVE AGENT; PEFLOXACIN;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG MONITORING; FEMALE; HUMAN;

ADOLESCENT; ANEMIA, APLASTIC; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CHILD; CYSTIC FIBROSIS; DRUG MONITORING; FEMALE; HUMANS; PEFLOXACIN;

EID: 0033648359     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Stahlmann R., Furster C., van Sickle D. Quinolones in children: are concerns over arthropathy justified? Drug Safety 1993; 9: 6: 397-403.
2. Hayem G., Carbon C. A reappraisal of quinolone tolerability. Experience of their musculosceletal adverse effects. Drug Safety 1996; 13: 6: 338-342.